Zolbetuximab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Zolbetuximab: From Gastric Cancer to Diabetic Cataract
One-Sentence Summary
Zolbetuximab is a monoclonal antibody that targets Claudin 18.2 (CLDN18.2). It is used for CLDN18.2-positive gastric and gastroesophageal junction cancer. The TxGNN model predicts it may be effective for diabetic cataract, but there are currently 0 clinical trials and 0 publications supporting this direction. This is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HER2-negative, CLDN18.2-positive unresectable advanced/recurrent gastric or gastroesophageal junction cancer (from pharmacology data; the Singapore licence text is blank) |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. From the pharmacology information, zolbetuximab is an antibody against CLDN18.2. It is thought to kill CLDN18.2-expressing tumour cells through antibody-dependent and complement-dependent cytotoxicity.
The prediction is hard to justify biologically. CLDN18.2 is not known to be expressed or to have a functional role in lens tissue. Diabetic cataract is driven mainly by the polyol pathway and oxidative stress. The high score (98.49%) is a graph-based computational result and likely reflects network artefacts rather than real pharmacology. The other top predictions are also eye conditions, including other cataract subtypes (mature, immature, senile, nuclear, cortical, tetanic, craniostenosis-associated and type 2 diabetes-associated) and diabetic retinopathy. They share the same weakness: no mechanistic link, no trials and no literature.
Clinical practice also argues against this use. Cataract is treated effectively by surgery. A systemically administered cytotoxic-effector antibody with known gastrointestinal toxicity (nausea, vomiting) would be a poor risk-benefit fit.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17197P | VYLOY™ Powder for Concentrate for Solution for Infusion 100 mg/vial | Lyophilised powder for injection (solution for infusion) | Not listed in the licence record |
The manufacturer is Baxter Oncology GmbH. The licence is valid and covers a single-ingredient product.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (monoclonal antibody against CLDN18.2 with immune-effector-mediated cell killing) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Nausea and vomiting are recognised toxicities; refer to the package insert for the grading |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: One pharmacology record was found. It identifies the drug's target, claudin 18 (CLDN18), and is not a drug-drug interaction with a co-administered drug. No interaction severity level is provided.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a graph-based model score. There are no clinical trials or publications, and no plausible mechanistic link between CLDN18.2 targeting and lens or retinal disease. The risk-benefit profile of a systemic cytotoxic-effector antibody in a surgically treatable condition is also unfavourable.
To proceed, the following is needed:
- Evidence that CLDN18.2 is expressed or functionally relevant in lens tissue (preclinical or mechanistic studies)
- Detailed mechanism of action data
- The Singapore package insert warnings and contraindications, to allow safety screening
- Any clinical or literature evidence for the predicted indication, which is currently absent
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.